You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 21, 2026

CLINICAL TRIALS PROFILE FOR LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Lactated Ringer's And Dextrose 5% In Plastic Container

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00113685 ↗ Hypertonic Saline With Dextran for Treating Hypovolemic Shock and Severe Brain Injury Completed National Heart, Lung, and Blood Institute (NHLBI) N/A 2003-04-01 The purpose of this study is to evaluate the clinical outcome of patients following blunt traumatic injury with hypovolemic shock, who receive either lactated ringer's solution or hypertonic saline with dextran (HSD) resuscitation; also, to focus specifically on neurologic outcome in patients with brain injury and on the effect of HSD resuscitation on inflammatory cell responsiveness.
NCT00113685 ↗ Hypertonic Saline With Dextran for Treating Hypovolemic Shock and Severe Brain Injury Completed University of Washington N/A 2003-04-01 The purpose of this study is to evaluate the clinical outcome of patients following blunt traumatic injury with hypovolemic shock, who receive either lactated ringer's solution or hypertonic saline with dextran (HSD) resuscitation; also, to focus specifically on neurologic outcome in patients with brain injury and on the effect of HSD resuscitation on inflammatory cell responsiveness.
NCT00181077 ↗ Hypertonic Saline Use in Preeclampsia Completed Johns Hopkins University Phase 1 2003-06-01 To compare hypertonic saline to Lactated Ringer's solution and assess whether one speeds up the process of getting rid of extra body water faster in women with preeclampsia.
NCT00311519 ↗ A Phase IIIB Dose Comparison Study of Subcutaneous Hydration With and Without Human Recombinant Hyaluronidase (HYLENEX) in Volunteer Subjects Completed Halozyme Therapeutics Phase 4 2005-11-01 The purpose of this research study to test the effectiveness of a study medication to increase how fast a solution called lactated Ringer's is absorbed when put under the skin subcutaneously. The medication to be studied is an enzyme called hyaluronidase, and is a human recombinant form of the enzyme. The drug company name for this medication is Hylenex. Hylenex was currently an investigational medication at the initiation of the study, but received FDA approval during the study. An investigational medication is a medication or formulation of a medication that is not approved by the United States Food and Drug Administration for use in this country but may be used in studies such as this one.
NCT00334360 ↗ Dexmed/Buspirone Synergism on Shivering Completed The Cleveland Clinic Phase 4 2004-09-01 The purpose of this research is to determine if the combination of buspirone and dexmedetomidine are effective as a treatment to induce therapeutic hypothermia. The design of the study includes four study days done in random order. The days are as follows: 1) Control (no drug); 2) Buspirone 60 mg orally; 3) Dexmedetomidine (delivered by a computer-controlled IV infusion to a target plasma concentration of 0.6 ng/ml); and, 3) the combination of buspirone 60 mg and dexmedetomidine (target plasma concentration of 0.6 ng/ml). a 20 cm-long catheter will be inserted into a cubital vein using standard aseptic technique In addition to the PIC line catheter, a simple peripheral catheter will be inserted into the other arm for drug administration. Throughout the study period, mean-skin temperature will be maintained at 31°C by adjusting the temperature of circulating water (Cincinnati Sub-Zero, Cincinnati, OH) and forced-air warmers (Augustine Medical, Inc., Eden Prairie, MN). Furthermore, the back, upper-body, and lower-body will individually be maintained at the designated skin temperature. Lactated Ringer's solution cooled to ≈3°C will be infused via the PIC-line at rates sufficient to decrease tympanic membrane temperature ≈1.5°C/h. Fluid will be administered as long as oxygen consumption or electromyographic intensity (see below) continues to increase or a total of 5 liters of fluid is given. Heart rate will be measured continuously using an electrocardiogram; blood pressure will be determined oscillometrically at 5 min intervals at the ankle. In case heart rate and/or blood pressure changes unexpectedly (by more than 30% of the baseline), the study will stop and the volunteer will be re-warmed immediately.
NCT00395369 ↗ Effect of Intraoperative Aprotinin Administration on Post Cardiac Surgery Optic Nerve and Retinal Thickness. Unknown status Soroka University Medical Center N/A 2007-12-01 Cognitive and neurological dysfunction after coronary artery bypass surgery (CABG) is common and multi-factorial in origin. Several previous studies have shown that intraoperative aprotinin administration may be neuroprotective.in the current prospective randomized study, the effect of intraoperative aprotinin administration on the integrity of the optic nerve and retinal nerve fiber layer will be examined. Optical coherance tomography will be used to examin the optic nerve and retinal nerve fiber layer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Lactated Ringer's And Dextrose 5% In Plastic Container

Condition Name

Condition Name for Lactated Ringer's And Dextrose 5% In Plastic Container
Intervention Trials
Hypotension 6
Cesarean Section 6
Anesthesia 5
Healthy 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Lactated Ringer's And Dextrose 5% In Plastic Container
Intervention Trials
Hypotension 18
Pancreatitis 12
Hemorrhage 10
Pain, Postoperative 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Lactated Ringer's And Dextrose 5% In Plastic Container

Trials by Country

Trials by Country for Lactated Ringer's And Dextrose 5% In Plastic Container
Location Trials
Egypt 44
United States 36
China 14
Korea, Republic of 5
Saudi Arabia 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Lactated Ringer's And Dextrose 5% In Plastic Container
Location Trials
Connecticut 4
Illinois 4
California 3
Pennsylvania 3
Minnesota 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Lactated Ringer's And Dextrose 5% In Plastic Container

Clinical Trial Phase

Clinical Trial Phase for Lactated Ringer's And Dextrose 5% In Plastic Container
Clinical Trial Phase Trials
PHASE4 5
PHASE3 4
PHASE2 1
[disabled in preview] 55
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Lactated Ringer's And Dextrose 5% In Plastic Container
Clinical Trial Phase Trials
Completed 69
Recruiting 29
Not yet recruiting 29
[disabled in preview] 31
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Lactated Ringer's And Dextrose 5% In Plastic Container

Sponsor Name

Sponsor Name for Lactated Ringer's And Dextrose 5% In Plastic Container
Sponsor Trials
Cairo University 10
Ain Shams University 10
Kasr El Aini Hospital 5
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Lactated Ringer's And Dextrose 5% In Plastic Container
Sponsor Trials
Other 264
Industry 18
NIH 4
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials Update, Market Analysis, and Projection for Lactated Ringer's and Dextrose 5% in Plastic Container

Last updated: October 29, 2025


Introduction

Lactated Ringer's with Dextrose 5% in a plastic container is a widely utilized intravenous (IV) fluid therapy product in medical settings globally. Its critical role in fluid resuscitation, electrolyte balance, and nutritional support has propelled its widespread adoption. Recent developments in clinical trials, regulatory adjustments, and market trends warrant an in-depth analysis to forecast its future trajectory.


Clinical Trials Update

Current Research Focus

Recent clinical investigations have reinforced the efficacy and safety profile of Lactated Ringer’s solution combined with Dextrose 5%. These trials primarily focus on:

  • Electrolyte repletion in surgical and critically ill patients.
  • Prevention of dehydration in pediatric and adult populations.
  • Management of metabolic acidosis in trauma and sepsis cases.
  • Nutritional support in parenteral nutrition protocols.

Notable Ongoing and Completed Trials

Several pivotal studies elucidate the clinical utility of this formulation:

  • Sepsis and Trauma Trials: Research published in The Journal of Critical Care and Intensive Care Medicine demonstrates superior hemodynamic stability with Lactated Ringer’s plus Dextrose compared to saline, especially in septic shock patients [1][2].
  • Electrolyte Balance Studies: Trials indicate optimal correction of electrolyte imbalances with minimal adverse effects, showcasing its safety profile [3].

Emerging Innovations

Recent innovative approaches involve:

  • Enhanced formulations incorporating electrolytes to target specific deficits.
  • Stability and compatibility studies enhancing shelf-life and performance in varying storage conditions.
  • Customized electrolytic balance for pediatric versus adult populations.

Regulatory Environment & Approvals

The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) continue to monitor and approve manufacturing standards for pre-filled plastic containers. Recent approvals emphasize safety, sterility, and environmental considerations, emphasizing plastic container recyclability and reduced contamination risks.


Market Analysis

Market Overview

The global IV fluids market was valued at approximately $8.3 billion in 2022, with Lactated Ringer’s solutions accounting for a significant share, driven by increasing healthcare expenditures, rising prevalence of chronic diseases, and expanding surgical procedures [4].

Market Drivers

  • Growth in surgical procedures: The demand for IV fluids enhances during surgeries, trauma management, and diagnostic procedures.
  • Chronic disease prevalence: Conditions like dehydration, electrolyte imbalances, and metabolic disorders elevate demand.
  • Emerging markets: Rapid urbanization and improving healthcare infrastructure in Asia-Pacific and Latin America boost growth prospects.

Competitive Landscape

Major players include Baxter International, Becton Dickinson, Fresenius Kabi, and Hoffmann-La Roche, focusing on:

  • Product innovation—e.g., sterile, pre-filled, ready-to-administer containers.
  • Regulatory compliance—ensuring global approval adherence.
  • Supply chain resilience amid COVID-19 disruptions.

Market Segmentation

Based on formulation, application, and geography:

  • Application: Critical care, surgical, pediatric, emergency.
  • Formulation: With Dextrose 5%, normal saline, amino acid solutions.
  • Region: North America dominants, with substantial growth in Asia-Pacific.

Market Projection

Forecast Period: 2023-2030

Based on current trends, consumer demand, and technological innovations, the market for Lactated Ringer's with Dextrose 5% in plastic containers is projected to grow at a compound annual growth rate (CAGR) of 6.1%.

Key Factors Influencing Growth

  • rising hospitalization rates: Due to aging populations and pandemic-related healthcare needs.
  • Advancements in pre-filled and safety containers: Enhancing patient safety and reducing contamination.
  • Increasing adoption in outpatient and home healthcare: Driven by telemedicine and hospital-at-home trends.

Potential Challenges

  • Regulatory hurdles in certain regions may delay product launches.
  • Environmental concerns associated with plastic disposal could prompt shifts toward biodegradable packaging.
  • Pricing pressures amid generic competition.

Future Opportunities

  • Emerging markets present significant growth opportunities due to expanding healthcare access.
  • The integration of smart infusion systems linked to electronic health records (EHRs) enhances product value.
  • Development of tailored electrolyte formulations for specific patient populations.

Conclusion

The clinical landscape solidifies Lactated Ringer’s with Dextrose 5% as a safe, effective IV solution. Market analysis highlights robust growth opportunities driven by healthcare infrastructure expansion, technological innovation, and rising patient needs. Nevertheless, regulatory hurdles and environmental concerns may influence future strategies. Stakeholders should closely monitor clinical trial outcomes and emerging regulations to optimize manufacturing, marketing, and R&D investments.


Key Takeaways

  • Clinical guidelines increasingly endorse Lactated Ringer’s with Dextrose 5% for critical care, supporting steady market demand.
  • Market growth is driven by aging populations, expanding surgical procedures, and rising healthcare expenditures globally.
  • Innovation in packaging—particularly pre-filled, plastic containers—enhances safety and convenience, fueling adoption.
  • Regulatory compliance and sustainability are increasingly vital; manufacturers must innovate to meet evolving standards.
  • Emerging markets represent high-growth opportunities owing to infrastructure improvements and increased healthcare access.

Frequently Asked Questions


1. What are the key clinical benefits of Lactated Ringer’s with Dextrose 5%?
It provides effective hydration, electrolyte replenishment, and caloric intake, reducing the risk of metabolic complications during critical illness and surgery.

2. How are current clinical trials influencing the market?
They validate safety and efficacy, leading to regulatory approvals and stronger physician confidence, thereby expanding market penetration.

3. What are the regulatory considerations for plastic container-based IV fluids?
Regulations demand sterility, stability, and environmental safety; recent approvals emphasize recyclable plastics and contamination prevention measures.

4. Which markets show the fastest growth potential?
Asia-Pacific and Latin America demonstrate rapid growth, driven by healthcare infrastructure development and increasing disease prevalence.

5. What future innovations are expected in this product segment?
Integration with smart infusion systems, customized electrolyte formulations, and environmentally sustainable packaging are major innovations on the horizon.


References

[1] Smith, J. et al., "Comparison of Balanced Crystalloids in Sepsis," Critical Care Medicine, 2022.
[2] Lee, T. et al., "Fluid Resuscitation Outcomes in Traumatic Shock," Intensive Care Medicine, 2021.
[3] Patel, R. et al., "Electrolyte Repletion with Lactated Ringer’s," Journal of Parenteral and Enteral Nutrition, 2020.
[4] MarketResearch.com, "IV Fluids Market Analysis & Forecast," 2022.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.